Venous Thromboembolism Prophylaxis With Enoxaparin After Ischemic Stroke
Prophylactic-dose subcutaneous heparin (unfractionated heparin or low-molecular-weight heparin [LMWH]) is reasonable in patients with acute ischemic stroke (AIS) who have impaired mobility and no contraindications to chemical prophylaxis (Class 2a, Level B-R). [1]
Prophylactic enoxaparin should be initiated within 2 days of symptom onset in hospitalized AIS patients who have no contraindications. [2]
Indication for Enoxaparin Initiation
Enoxaparin prophylaxis is indicated for AIS patients with impaired mobility as a strategy to reduce VTE risk. [1]
LMWH should be considered in immobile AIS patients when the expected benefit of reducing VTE risk offsets the increased risk of intracranial and extracranial bleeding. [3]
Initiation Timing After Symptom Onset
Prophylactic-dose enoxaparin should be started within 48 hours of symptom onset in the absence of contraindications. [2]
Practical Initiation Criteria
Initiation should be withheld in the presence of contraindications to anticoagulant prophylaxis. [1]
Initiation should follow clinical selection for prophylactic anticoagulation in immobile AIS patients. [3]
Dose Selection (Prophylactic vs Therapeutic)
Enoxaparin should be used at prophylactic dosing intended for VTE prevention rather than at therapeutic anticoagulation intensity. [2]
Key Evidence Supporting Early Prophylactic Strategy
The AHA/ASA guideline supports prophylactic-dose subcutaneous UFH or LMWH in AIS patients with impaired mobility and no contraindications (Class 2a, Level B-R). [1]
A performance-measure summary (eCQI) supports administration of VTE prophylaxis anticoagulants within 2 days of symptom onset to reduce stroke mortality and morbidity when no contraindications exist. [2]
Common Pitfalls to Avoid
Chemical prophylaxis should not be initiated despite contraindications to anticoagulation. [1]
Mechanical prophylaxis alone should not be substituted for chemical prophylaxis when chemical prophylaxis has been selected for an immobile AIS patient without contraindications. [1]
Treatment Goals After Initiation
The treatment goal is reduction of VTE risk (including DVT and PE) in AIS patients with impaired mobility. [1]